Navigation Links
BD Announces FDA 510(k) Clearance of BD Vacutainer(R) Rapid Serum Blood Collection Tube

FRANKLIN LAKES, N.J., Oct. 6 /PRNewswire/ -- BD Diagnostics - Preanalytical Systems, a unit of BD (Becton, Dickinson and Company), announced today it received U.S. Food and Drug Administration (FDA) 510(k) clearance for the BD Vacutainer® Rapid Serum Tube, a blood collection device designed to help acute healthcare facilities rapidly analyze blood serum for patient diagnosis.

"Blood test results drive many important medical decisions, including how to treat or medicate patients," said Ana Stankovic, MD, Vice President, Medical and Scientific Affairs and Clinical Operations for BD Diagnostics - Preanalytical Systems. "Technologies such as the BD Vacutainer Rapid Serum Tube can help reduce the time it takes to get answers from blood tests and have a significant impact on patient care and hospital productivity."

The new BD Vacutainer Rapid Serum Tube is the first serum blood collection tube with a gel additive to be launched in the United States that can be centrifuged only five minutes after the tube is filled. Standard serum tubes require a 30-minute clot time prior to centrifugation. This reduction in clot time significantly shortens sample processing time and the time it takes for clinical laboratory professionals to begin analyzing and getting test results.

"By taking essentially one sixth of the time of standard serum tubes to clot, the BD Vacutainer Rapid Serum Tube is poised to help facilities significantly improve patient throughput, especially in places like emergency rooms where decisions to admit or treat patients are often based on blood test results," said Stankovic.

About BD Vacutainer Blood Collection Products

The widely accepted standard of collecting blood (phlebotomy) for medical diagnostic analysis is performed with a phlebotomy needle and evacuated tube. The vacuum force inside the tube gently draws blood from the patient's vein through the phlebotomy needle and into the evacuated tube. BD offered the first such device for sale in 1949, the Evacutainer, which was invented by Joseph Kleiner. Producing more than 4 billion units annually for use in human healthcare, veterinary care and medical research, BD remains the world's largest manufacturer of evacuated blood collection tubes.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit

SOURCE BD-Becton Dickinson

SOURCE BD-Becton Dickinson
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... , , , WHEN: , , ... , , , LOCATION: , , , Online, with free registration ... PANELISTS:  , , , Frost & Sullivan,s Global Vice President of ... Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... witnessing an exceptional era. Several new demand spaces, such as innovative ...
(Date:6/23/2016)... N.J. , June 23, 2016  Guerbet announced ... Premier Inc.,s Supplier Horizon Award . ... year, Guerbet was recognized for its support of Premier ... creation through clinical excellence, and commitment to lower costs. ... to receive this recognition of our outstanding customer service ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer ... through a fitness app. The fitness app plans to fix the two major problems leading ... a one size fits all type program , They don’t eliminate all the ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
Breaking Medicine News(10 mins):